Product Information
FENOFIBRATE 160 MG TABLET is a generic product labeled by Rhodes Pharmaceuticals L.P., priced at $0.1033 per EA under NDC 42858066045. Its NADAC has been published 482 times since Jul 12, 2017.
FDA first approved this application on May 13, 2005. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
160 mg/1
Manufacturer
Rhodes Pharmaceuticals L.P.NDC
42858066045
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FENOFIBRATEApproval Type
Generic (ANDA)
FDA Application
ANDA076433FDA Approved
5/13/2005
TE Code
AB
On Market Since
6/1/2017
Pharmacological Classes
Price Statistics
The NADAC for FENOFIBRATE 160 MG TABLET has been published 482 times since Jul 12, 2017, and over the history we have for it it has declined 79.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1033 per EA |
|---|---|
| All-time high | $0.4937 (Jul 12, 2017) |
| All-time low | $0.0892 (Dec 17, 2025) |
| 52-week high | $0.1259 |
| 52-week low | $0.0892 |
| Median price | $0.1881 |
| Average price | $0.2191 |
| Largest weekly change | +41.1% (Jan 17, 2024) |
| Weeks tracked | 482 |
| Tracking since | Jul 12, 2017 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rhodes Pharmaceuticals L.P. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Fenofibrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FENOFIBRATE 160 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for FENOFIBRATE 160 MG TABLET, manufactured by Rhodes Pharmaceuticals L.P., is $0.1033 per EA (NDC 42858066045), effective Sep 30, 2026.
How has the price of FENOFIBRATE 160 MG TABLET changed over time?
Over the history we have for it, the NADAC for FENOFIBRATE 160 MG TABLET has declined 79.1%. It has been tracked across 482 weekly CMS publications since Jul 12, 2017.
What are the highest and lowest recorded NADAC prices for FENOFIBRATE 160 MG TABLET?
Since Jul 12, 2017, the NADAC for FENOFIBRATE 160 MG TABLET has ranged from a low of $0.0892 (Dec 17, 2025) to a high of $0.4937 (Jul 12, 2017), with a median of $0.1881 per EA.
Are there cheaper alternatives to FENOFIBRATE 160 MG TABLET?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, FENOFIBRATE 160 MG TABLET, is $0.1008 per EA — about 2% below FENOFIBRATE 160 MG TABLET.
Who manufactures FENOFIBRATE 160 MG TABLET?
FENOFIBRATE 160 MG TABLET (NDC 42858066045) is labeled by Rhodes Pharmaceuticals L.P., and CMS classifies it as a generic product.